Comparison

Halofuginone (hydrobromide) European Partner

Item no. HY-N1584A-100mg
Manufacturer MedChem Express
CASRN 64924-67-0
Amount 100 mg
Quantity options 100 mg 10 mM/1 mL 10 mg 25 mg 500 mg 50 mg 5 mg
Category
Type Inhibitors
Specific against other
Purity 99.99
Citations [1]Tsuchida K, et al. Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation. Free Radic Biol Med. 2017 Feb;103:236-247.|[2]Keller TL, et al. Halofuginone and other Febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol. 2012 Feb 12;8(3):311-7.|[3]Cui Z, et al. Halofuginone attenuates osteoarthritis by inhibition of TGF-β activity and H-type vessel formation in subchondral bone. Ann Rheum Dis. 2016 Sep;75(9):1714-21.|[4]Tracy L McGaha, et al. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol. 2002 Mar;118(3):461-70.|[5]Pritesh P Jain, et al. Halofuginone, a Promising Drug for Treatment of Pulmonary Hypertension. Br J Pharmacol. 2021 Mar 10.
Hum Gene Ther. 2021 Aug 18.|ACS Infect Dis. 2023 Mar 15.|Br J Pharmacol. 2021 Mar 10.|Cell Metab. 2023 Nov 11:S1550-4131(23)00385-6.|Fish Shellfish Immunol. 2024 Jun 25:109727.|Friedrich-Alexander University Erlangen-Nuremberg. 2023 May 2.|Indian J Hematol Blood Transfus. 2024 Mar 25.|iScience. 2023 Mar.|J Funct Foods. 2024 Jul.|J Tissue Eng Regen Med. 2021 Aug 7.|Photodiagnosis Photodyn Ther. 2021 Oct 7;102572.
Smiles O=C1N(CC(C[C@@H]2NCCC[C@H]2O)=O)C=NC3=C1C=C(Cl)C(Br)=C3.Br
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias RU-19110 (hydrobromide)
Shipping Condition Room temperature
Available
Manufacturer - Type
Natural Products
Manufacturer - Applications
COVID-19-anti-virus
Manufacturer - Targets
Calcium Channel; DNA/RNA Synthesis; Parasite; Sodium Channel; TGF-beta/Smad
Shipping Temperature
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Molecular Weight
495.59
Product Description
Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM[1][2]. Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity[3][4]. Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects[5].
Manufacturer - Research Area
Cancer; Infection; Inflammation/Immunology; Cardiovascular Disease
Solubility
DMSO: 50 mg/mL (ultrasonic)|H2O: 2.6 mg/mL (ultrasonic)
Manufacturer - Pathway
Anti-infection; Cell Cycle/DNA Damage; Membrane Transporter/Ion Channel; Neuronal Signaling; Stem Cell/Wnt; TGF-beta/Smad
Isoform
Plasmodium
Clinical information
Phase 2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close